Gossamer Bio, Inc. filed a Form 8-K on September 16, 2026, disclosing the appointment of Gregory A. Ciongoli as a Class III director and member of the Audit Committee, effective September 16, 2026.
Key Highlights
- New director appointed: Gregory A. Ciongoli, age 51, was appointed as a Class III director with an initial term expiring at the 2027 annual meeting of stockholders.
- Audit Committee membership: The Board also appointed Mr. Ciongoli as a member of the Audit Committee.
- Annual cash retainers: Mr. Ciongoli will receive $40,000 per year for Board service and $7,500 per year for Audit Committee service under the company's non-employee director compensation program.
- Equity award timing deferred: The Board determined that a standard initial equity award to Mr. Ciongoli will be made at a future date and in a future amount to be determined by the Board.
- Prior PIPE participation: Mr. Ciongoli was a purchaser in the company's 2026 private placement transaction, which had an initial closing on August 24, 2026.
- Independence determination: The Board determined that Mr. Ciongoli is an independent director in accordance with the listing requirements of the Nasdaq Global Select Market.
Ciongoli's Background and Compensation Terms at Gossamer Bio
According to the filing, Mr. Ciongoli has served as the Founder and Managing Partner of Adiumentum Capital Management, a Boston-based investment firm, since April 2024. Prior to that role, he was a Partner at the Baupost Group from 2007 to 2024, where the filing states he "worked on a broad range of public and private equity investments." He holds an A.B. from Princeton University and an M.B.A. from Harvard Business School. The filing also notes that he currently serves on the boards of REGENXBIO Inc. since August 2026, Zymeworks, Inc. since August 2025, and Atara Biotherapeutics, Inc. since September 2024, and has served as chair of the Atara board since September 2025.
Under Gossamer Bio's non-employee director compensation program, Mr. Ciongoli will receive annual cash retainers of $40,000 for Board service and $7,500 for Audit Committee service, according to the filing. The filing discloses that Mr. Ciongoli also entered into the company's standard form of Indemnification Agreement, the form of which was originally filed as Exhibit 10.14 to the company's Form S-1 on December 21, 2018. The filing states there is "no arrangement or understanding between Mr. Ciongoli and any other person pursuant to which Mr. Ciongoli was appointed as a director."
The filing discloses that Mr. Ciongoli participated in the company's 2026 private placement (the "2026 PIPE"), purchasing initial closing pre-funded warrants exercisable for, following stockholder approval, approximately 22,337 shares of common stock. He has also agreed to purchase second closing pre-funded warrants potentially covering approximately 111,687 shares of common stock and FDA approval warrants potentially covering approximately 66,845 shares of common stock, with all figures reflecting the company's 1-for-80 reverse stock split effectuated on September 10, 2026, as noted in the filing. The securities are registered on NASDAQ:GOSS.
What Was Disclosed
Gossamer Bio disclosed the appointment of Gregory A. Ciongoli as a Class III director and Audit Committee member, his compensation terms, his prior participation in the 2026 PIPE, and the Board's determination of his independence under Nasdaq listing requirements.




Please wait processing your request...